Fertility decline & demographic stagnation
Every developed country is below replacement. Under-counted by EA and e/acc. Civilizationally large.
The scale of it
global total fertility rate (births per woman)
The capital on it
Fertility-tech VC (IVF access, egg freezing, reproductive health) plus nascent pronatal-policy philanthropy. Excludes national family-benefit transfers — large, but compensating the problem rather than solving its cost structure.
source: Fertility-tech / femtech venture tracking (PitchBook, FemHealth Insights; estimate) · confidence low · estimate, improvable by PR
The prize at the limit
If demographic decline is the slow crisis of the century, the company that makes having children radically cheaper, easier, and more reliable (IVF access, artificial gametes, fertility restoration) serves an entire generation and is quietly backed by every aging state.
comparable: a reproductive-health + IVF platform at global scale · confidence low · a ceiling, not a forecast
The trade: demand is high, only $1B/yr of capital is flowing (0.008× its fair share), and the prize at the limit is $200B. This is a Request for Startups and a Request for Investors at once.
The summary lives here. The full whitepaper walks through the four-axis ranking, existing alternatives, proposed direction, cost & scale, and suggested investors — in the spirit of Hyperloop Alpha.
Quantity · humans affected
source: UN World Population Prospects
Severity · WTP / wealth
share of affected person’s wealth they would pay for a solution
Current solutions
quality of existing solutions — low score = high opportunity
Market size · TAM
USD / year the world is already paying
Time · OOM to impact
order-of-magnitude horizon to civilizational-scale impact
Capital · OOM to solve
cumulative R&D + deployment + supply chain across the arc
Priority score
13
importance × urgency, 0–100
Importance
13
humans affected × severity, gated by market
Urgency
94
direction of travel + solution gap
Neglectedness
7/10Treated as inevitable rather than as a solvable problem; very little serious work on the cost and culture of family formation.
medTractability
3/10Pro-natal policy levers have shown weak effects so far; the affordability and IVF-cost wedges are more promising but unproven at scale.
lowWays to help
Order-of-magnitude cheaper IVF, or bundle down the marginal cost of raising a child.
Study what actually moves family formation, separate from ideology.
Organizations
People to follow
- Lyman Stonedemographer
- Catherine Pakalukeconomist of the family
Three-lens scoring
Global fertility has fallen to ~2.3 and is projected to drop below 2.1 (replacement) within a decade. South Korea, Italy, Japan, and China are already at 0.7-1.3. Shrinking working-age populations break pension systems, slow innovation, and collapse housing markets. Causes: housing cost, childcare cost, cultural shift, biological fertility decline. Solutions span policy (childcare subsidies, YIMBY), technology (in-vitro gametogenesis, artificial wombs), and culture. Severely neglected in EA/e/acc canon.
The success vision · 30 years horizon
If we solve this, here is the world we get.
Before · today
TFR <2.1 in nearly every developed nation and approaching it in developing ones. Demographic collapse + dependency-ratio crisis baked in for the next 50+ years absent intervention.
After · 30 years
TFR above replacement in most willing societies. Family formation affordable, supported, and culturally celebrated. Demographic stability restored.
Voices on this quest
2 thinkers“Population collapse due to low birth rates is a much bigger risk to civilization than global warming.”
Population collapse from low birth rates is a larger civilizational risk than most mainstream X-risk. Has stated this repeatedly across years.
Public statements, 2022-2024
Demographic stagnation and complacency are under-discussed civilizational risks. Cultural risk aversion compounds into stagnation.
The Complacent Class (2017)
Companies on this quest
4 mappedWomen-focused fertility clinic network, IVF, egg freezing, family planning. Direct-to-employer model.
Engineered ovarian cells to improve IVF and delay menopause. Clinical-stage trials underway.
In-vitro gametogenesis, generating eggs from stem cells. Directly addresses age-related fertility decline.
At-home male fertility testing and sperm freezing. Sperm quality has fallen ~50% in 40 years; market lagging.